Loading...
Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of ankylosing spondylitis (AS) in the USA and for AS and non-radiographic axial spondyloarthritis (nr-axSpA) in Europe and in some Latin American countries. CZP lacks Fc region, prev...
Saved in:
| Published in: | Open Access Rheumatol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Dove Medical Press
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5944451/ https://ncbi.nlm.nih.gov/pubmed/29765257 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OARRR.S116654 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|